CeriBell, Inc. (CBLL) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Balance Sheet ⢠Cash Burn ⢠Margin Pressure CBLL has a strong liquidity cushion and high gross margins, but persistent operating losses, negative cash flow, and weak efficiency continue to outweigh those strengths despite a still-rich valuation.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Range-bound recovery ⢠Breakout needed Support Level: $17.10 to $17.50 Resistance Level: $18.75 to $18.80 CBLL has improved over the last month with higher lows above $18, but it remains range-bound and needs a break above $18.75-$18.80 while holding $17.10-$17.50 to confirm a stronger uptrend.
Sentiment & News
Key News Insights: ⢠Hospital expansion ⢠Clinical validation ⢠Adjacent use cases Ceribell showed strong hospital growth and expanding clinical validation, reinforcing commercialization momentum and broader medical utility for its AI seizure platform.
AI Summary
CBLL has moved from a speculative medtech story to one with real commercial traction and clinical validation, but with operating costs and cash burn still outrunning revenue, the stock only works if new account growth and higher utilization quickly translate into operating leverage and margin discipline.
Description
CeriBell, Inc. develops point-of-care EEG technology that uses AI to support detection and management of neurological conditions in acute care settings. Its Ceribell System pairs a bedside EEG platform with disposable headbands and portable recorders to enable rapid monitoring outside traditional neurodiagnostic labs. The company was incorporated in 2014, changed its name from Brain Stethoscope, Inc. in 2015, and is based in Sunnyvale, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 12 | Dec 19 | CBLL | CeriBell, Inc. | Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential. | Closed | +1.2% |